

**1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING****Product Identifier****Material Name:** Spironolactone and Hydrochlorothiazide Tablets (Greenstone LLC)**Trade Name:** Not applicable**Chemical Family:** Mixture**Relevant Identified Uses of the Substance or Mixture and Uses Advised Against****Intended Use:** Pharmaceutical product used as antihypertensive diuretic**Details of the Supplier of the Safety Data Sheet**Greenstone LLC  
100 Route 206 North  
Peapack, NJ 07977  
800-435-7095**Emergency telephone number:**  
CHEMTREC (24 hours): 1-800-424-9300**2. HAZARDS IDENTIFICATION****Classification of the Substance or Mixture****GHS - Classification**

Reproductive Toxicity: Category 1B

Carcinogenicity: Category 2

**EU Classification:**

EU Indication of danger: Carcinogenic: Category 3

Toxic to Reproduction: Category 2

## EU Risk Phrases:

R40 - Limited evidence of a carcinogenic effect

R61 - May cause harm to the unborn child.

**Label Elements****Signal Word:** Danger**Hazard Statements:** H360D - May damage the unborn child

H351 - Suspected of causing cancer

**Precautionary Statements:**

P202 - Do not handle until all safety precautions have been read and understood

P281 - Use personal protective equipment as required

P308 + P313 - IF exposed or concerned: Get medical attention/advice

P405 - Store locked up

P501 - Dispose of contents/container in accordance with all local and national regulations



## SAFETY DATA SHEET

**Material Name: Spironolactone and Hydrochlorothiazide  
Tablets (Greenstone LLC)  
Revision date: 11-May-2015**

**Page 2 of 13**

**Version: 2.0**

**Other Hazards** No data available  
**Australian Hazard Classification (NOHSC):** Hazardous Substance. Non-Dangerous Goods.

**Note:** This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

**Hazardous**

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Iron oxide	1309-37-1	215-168-2	Not Listed	Not Listed	*
Magnesium stearate	557-04-0	209-150-3	Not Listed	Not Listed	*
Hydrochlorothiazide	58-93-5	200-403-3	Not Listed	Not Listed	>1
Titanium dioxide	13463-67-7	236-675-5	Not Listed	Not Listed	*
Calcium sulfate, dihydrate	10101-41-4	Not Listed	Not Listed	Not Listed	*
Spironolactone	52-01-7	200-133-6	Repr.Cat.2;R61 Carc.Cat3;R40 Xn;R48/22	Carc.2 (H351) STOT RE.2 (H373) Repr.1B (H360D)	<10
Polyethylene glycol	25322-68-3	Not Listed	Not Listed	Not Listed	*
Corn Starch	9005-25-8	232-679-6	Not Listed	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Flavor	NOT ASSIGNED	Not Listed	Not Listed	Not Listed	*
Povidone	9003-39-8	Not Listed	Not Listed	Not Listed	*
Hydroxypropyl methylcellulose	9004-65-3	Not Listed	Not Listed	Not Listed	*
Hydroxypropyl cellulose	9004-64-2	Not Listed	Not Listed	Not Listed	*

**Additional Information:** \*\*\* per tablet/capsule/lozenge/suppository  
 \* Proprietary  
 Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.  
 In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

**For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16**

### 4. FIRST AID MEASURES

**Description of First Aid Measures**

**Eye Contact:** Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

**Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

## SAFETY DATA SHEET

Material Name: Spironolactone and Hydrochlorothiazide  
Tablets (Greenstone LLC)  
Revision date: 11-May-2015

Page 3 of 13

Version: 2.0

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

### Most Important Symptoms and Effects, Both Acute and Delayed

**Symptoms and Effects of Exposure:** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.  
**Medical Conditions Aggravated by Exposure:** None known

### Indication of the Immediate Medical Attention and Special Treatment Needed

**Notes to Physician:** None

## 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Extinguish fires with CO<sub>2</sub>, extinguishing powder, foam, or water.

### Special Hazards Arising from the Substance or Mixture

**Hazardous Combustion Products:** Toxic or corrosive gases including oxides of carbon and oxides of sulfur

**Fire / Explosion Hazards:** Not applicable

### Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

## 6. ACCIDENTAL RELEASE MEASURES

### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

### Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

### Methods and Material for Containment and Cleaning Up

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

**Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

## 7. HANDLING AND STORAGE

### Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

### Conditions for Safe Storage, Including any Incompatibilities

**Storage Conditions:** Store as directed by product packaging.

**Specific end use(s):** Pharmaceutical drug product

## SAFETY DATA SHEET

Material Name: Spironolactone and Hydrochlorothiazide  
Tablets (Greenstone LLC)  
Revision date: 11-May-2015

Page 4 of 13

Version: 2.0

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

#### Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

#### Iron oxide

ACGIH Threshold Limit Value (TWA)	5 mg/m <sup>3</sup>
Australia TWA	5 mg/m <sup>3</sup>
	10 mg/m <sup>3</sup>
Austria OEL - MAKs	5 mg/m <sup>3</sup>
	10 mg/m <sup>3</sup>
Belgium OEL - TWA	2 ppm
	5 mg/m <sup>3</sup>
Bulgaria OEL - TWA	5.0 mg/m <sup>3</sup>
Denmark OEL - TWA	3.5 mg/m <sup>3</sup>
Estonia OEL - TWA	3.5 mg/m <sup>3</sup>
Finland OEL - TWA	5 mg/m <sup>3</sup>
France OEL - TWA	5 mg/m <sup>3</sup>
Greece OEL - TWA	10 mg/m <sup>3</sup>
Hungary OEL - TWA	6 mg/m <sup>3</sup>
Ireland OEL - TWAs	5 mg/m <sup>3</sup>
	10 mg/m <sup>3</sup>
	4 mg/m <sup>3</sup>
Lithuania OEL - TWA	3.5 mg/m <sup>3</sup>
OSHA - Final PELs - TWAs:	10 mg/m <sup>3</sup>
	15 mg/m <sup>3</sup>
Poland OEL - TWA	5 mg/m <sup>3</sup>
Portugal OEL - TWA	5 mg/m <sup>3</sup>
Romania OEL - TWA	5 mg/m <sup>3</sup>
Slovakia OEL - TWA	1.5 mg/m <sup>3</sup>
Spain OEL - TWA	5 mg/m <sup>3</sup>
Sweden OEL - TWAs	3.5 mg/m <sup>3</sup>

#### Magnesium stearate

ACGIH Threshold Limit Value (TWA)	10 mg/m <sup>3</sup>
Lithuania OEL - TWA	5 mg/m <sup>3</sup>
Sweden OEL - TWAs	5 mg/m <sup>3</sup>

#### Hydrochlorothiazide

Manufacturer OEL:	250ug/m <sup>3</sup>
-------------------	----------------------

#### Titanium dioxide

ACGIH Threshold Limit Value (TWA)	10 mg/m <sup>3</sup>
ACGIH OELs - Notice of Intended Changes	Listed
Australia TWA	10 mg/m <sup>3</sup>
Austria OEL - MAKs	5 mg/m <sup>3</sup>
Belgium OEL - TWA	10 mg/m <sup>3</sup>
Bulgaria OEL - TWA	10.0 mg/m <sup>3</sup>
Denmark OEL - TWA	6 mg/m <sup>3</sup>
Estonia OEL - TWA	5 mg/m <sup>3</sup>
France OEL - TWA	10 mg/m <sup>3</sup>
Greece OEL - TWA	10 mg/m <sup>3</sup>
	5 mg/m <sup>3</sup>

## SAFETY DATA SHEET

Material Name: Spironolactone and Hydrochlorothiazide  
Tablets (Greenstone LLC)  
Revision date: 11-May-2015

Page 5 of 13

Version: 2.0

Ireland OEL - TWAs	10 mg/m <sup>3</sup>
	4 mg/m <sup>3</sup>
Latvia OEL - TWA	10 mg/m <sup>3</sup>
Lithuania OEL - TWA	5 mg/m <sup>3</sup>
OSHA - Final PELS - TWAs:	15 mg/m <sup>3</sup>
Poland OEL - TWA	10.0 mg/m <sup>3</sup>
Portugal OEL - TWA	10 mg/m <sup>3</sup>
Romania OEL - TWA	10 mg/m <sup>3</sup>
Spain OEL - TWA	10 mg/m <sup>3</sup>
Sweden OEL - TWAs	5 mg/m <sup>3</sup>

<b>Calcium sulfate, dihydrate</b>	
ACGIH Threshold Limit Value (TWA)	10 mg/m <sup>3</sup>
Germany (DFG) - MAK	1.5 mg/m <sup>3</sup>
	4 mg/m <sup>3</sup>
Portugal OEL - TWA	10 mg/m <sup>3</sup>
Spain OEL - TWA	10 mg/m <sup>3</sup>

<b>Spironolactone</b>	
Manufacturer OEL:	90ug/m <sup>3</sup> , Skin

<b>Polyethylene glycol</b>	
Austria OEL - MAKs	1000 mg/m <sup>3</sup>
Germany - TRGS 900 - TWAs	1000 mg/m <sup>3</sup>
Germany (DFG) - MAK	1000 mg/m <sup>3</sup> average molecular weight 200-600
Slovakia OEL - TWA	1000 mg/m <sup>3</sup>
Slovenia OEL - TWA	1000 mg/m <sup>3</sup>

<b>Corn Starch</b>	
ACGIH Threshold Limit Value (TWA)	10 mg/m <sup>3</sup>
Australia TWA	10 mg/m <sup>3</sup>
Belgium OEL - TWA	10 mg/m <sup>3</sup>
Bulgaria OEL - TWA	10.0 mg/m <sup>3</sup>
Czech Republic OEL - TWA	4.0 mg/m <sup>3</sup>
Greece OEL - TWA	10 mg/m <sup>3</sup>
	5 mg/m <sup>3</sup>
Ireland OEL - TWAs	10 mg/m <sup>3</sup>
	4 mg/m <sup>3</sup>
OSHA - Final PELS - TWAs:	15 mg/m <sup>3</sup>
Portugal OEL - TWA	10 mg/m <sup>3</sup>
Slovakia OEL - TWA	4 mg/m <sup>3</sup>
Spain OEL - TWA	10 mg/m <sup>3</sup>

### Exposure Controls

#### Engineering Controls:

General room ventilation is adequate unless the process generates dust, mist or fumes. Engineering controls should be used as the primary means to control exposures. Keep airborne contamination levels below the exposure limits listed above in this section.

#### Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

#### Hands:

Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

## SAFETY DATA SHEET

Material Name: Spironolactone and Hydrochlorothiazide  
Tablets (Greenstone LLC)  
Revision date: 11-May-2015

Page 6 of 13

Version: 2.0

**Eyes:** Wear safety glasses or goggles if eye contact is possible.  
**Skin:** Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.  
**Respiratory protection:** If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

<b>Physical State:</b>	Film-coated tablets	<b>Color:</b>	Tan
<b>Odor:</b>	No data available.	<b>Odor Threshold:</b>	No data available.
<b>Molecular Formula:</b>	Mixture	<b>Molecular Weight:</b>	Mixture

**Solvent Solubility:** No data available  
**Water Solubility:** No data available  
**pH:** No data available.  
**Melting/Freezing Point (°C):** No data available  
**Boiling Point (°C):** No data available.

**Partition Coefficient: (Method, pH, Endpoint, Value)**

**Povidone**

No data available

**Magnesium stearate**

No data available

**Corn Starch**

No data available

**Hydroxypropyl cellulose**

No data available

**Iron oxide**

No data available

**Titanium dioxide**

No data available

**Hydroxypropyl methylcellulose**

No data available

**Polyethylene glycol**

No data available

**Flavor**

No data available

**Calcium sulfate, dihydrate**

No data available

**Spironolactone**

Predicted 7.4 Log D 3.12

**Hydrochlorothiazide**

No data available

**Decomposition Temperature (°C):** No data available.

**Evaporation Rate (Gram/s):** No data available

**Vapor Pressure (kPa):** No data available

**Vapor Density (g/ml):** No data available

**Relative Density:** No data available

**Viscosity:** No data available

**Flammability:**

**Autoignition Temperature (Solid) (°C):** No data available

**Flammability (Solids):** No data available

**Flash Point (Liquid) (°C):** No data available

## SAFETY DATA SHEET

Material Name: Spironolactone and Hydrochlorothiazide  
Tablets (Greenstone LLC)  
Revision date: 11-May-2015

Page 7 of 13

Version: 2.0

Upper Explosive Limits (Liquid) (% by Vol.): No data available  
Lower Explosive Limits (Liquid) (% by Vol.): No data available

### 10. STABILITY AND REACTIVITY

**Reactivity:** No data available  
**Chemical Stability:** Stable under normal conditions of use.  
**Possibility of Hazardous Reactions**  
**Oxidizing Properties:** No data available  
**Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions.  
**Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers  
**Hazardous Decomposition Products:** No data available

### 11. TOXICOLOGICAL INFORMATION

#### Information on Toxicological Effects

**General Information:** The information included in this section describes the potential hazards of the individual ingredients.  
**Short Term:** Antihypertensive drug: has blood pressure-lowering properties  
**Long Term:** Repeat-dose studies in animals have shown a potential to cause adverse effects on blood kidneys reproductive system  
**Known Clinical Effects:** Signs and symptoms might include nausea, vomiting, cramps, dizziness, headache, vertigo, low blood pressure on standing, rash, urticaria, photosensitivity, electrolyte imbalance, muscle spasm, weakness, and restlessness. Hypersensitivity reactions may also occur in susceptible individuals. Effects on blood and blood-forming organs have also occurred. May cause adverse effects on the developing fetus.

#### Acute Toxicity: (Species, Route, End Point, Dose)

##### **Povidone**

Rat Oral LD50 100 g/kg

##### **Magnesium stearate**

Rat Oral LD50 > 2000 mg/kg  
Rat Inhalation LC50 > 2000 mg/m<sup>3</sup>

##### **Titanium dioxide**

Rat Oral LD50 > 7500 mg/kg  
Rat Subcutaneous LD50 50 mg/kg

##### **Hydroxypropyl methylcellulose**

Rat Oral LD50 > 10,000 mg/kg

##### **Spironolactone**

Rat Oral LD 50 4121 mg/kg  
Mouse Oral LD 50 >1000mg/kg  
Rabbit Oral LD 50 >1000mg/kg  
Rat Intraperitoneal LD 50 786mg/kg

##### **Hydrochlorothiazide**

## SAFETY DATA SHEET

Material Name: **Spironolactone and Hydrochlorothiazide  
Tablets (Greenstone LLC)**  
Revision date: **11-May-2015**

Page 8 of 13

Version: 2.0

### 11. TOXICOLOGICAL INFORMATION

Rat Oral LD 50 2750 mg/kg  
Mouse Oral LD 50 2830mg/kg  
Rat Intravenous LD 50 990mg/kg  
Dog Intravenous LD 50 250mg/kg

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

#### Irritation / Sensitization: (Study Type, Species, Severity)

##### **Polyethylene glycol**

Eye Irritation Rabbit Mild  
Skin Irritation Rabbit Mild

##### **Spironolactone**

Skin Sensitization - GPMT Guinea Pig No effect

#### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

##### **Spironolactone**

13 Week(s) Rat Oral 50 mg/kg LOAEL Blood  
78 Week(s) Rat Oral 50 mg/kg/day LOAEL Liver, Male reproductive system

##### **Hydrochlorothiazide**

30 Day(s) Rat Oral 1 g/kg/day LOAEL Blood  
13 Week(s) Mouse Oral 12,500 ppm LOAEL Bladder  
9 Month(s) Dog Oral 50 mg/kg/day LOAEL Endocrine system  
1 Year(s) Rat Oral 2000 ppm LOAEL Kidney  
2 Year(s) Rat Oral 250 ppm LOAEL Kidney

#### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

##### **Spironolactone**

Reproductive & Fertility Rat Oral 15 mg/kg/day NOAEL Fetotoxicity  
Reproductive & Fertility Rat Intraperitoneal 100 mg/kg/day LOAEL Fertility  
Embryo / Fetal Development Mouse Intraperitoneal 100 mg/kg/day LOAEL Maternal Toxicity  
Embryo / Fetal Development Rat Oral 50 mg/kg/day LOAEL Fetotoxicity  
Embryo / Fetal Development Rabbit Oral 20 mg/kg/day LOAEL Fetotoxicity

##### **Hydrochlorothiazide**

Reproductive & Fertility Rat Oral 1000 mg/kg LOAEL Maternal toxicity  
Reproductive & Fertility Mouse Oral 3000 mg/kg/day NOEL No effects at maximum dose  
Embryo / Fetal Development Rat Oral 1000 mg/kg/day NOEL Not Teratogenic  
Embryo / Fetal Development Mouse Oral 3000 mg/kg/day NOEL Not Teratogenic

#### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

##### **Spironolactone**

Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative  
Mammalian Cell Mutagenicity Negative without activation

##### **Hydrochlorothiazide**



## SAFETY DATA SHEET

Material Name: Spironolactone and Hydrochlorothiazide  
Tablets (Greenstone LLC)  
Revision date: 11-May-2015

Page 9 of 13

Version: 2.0

### 11. TOXICOLOGICAL INFORMATION

Bacterial Mutagenicity (Ames) *Salmonella* Negative  
*In Vitro* Sister Chromatid Exchange Chinese Hamster Ovary (CHO) cells Positive  
*In Vitro* Chromosome Aberration Chinese Hamster Ovary (CHO) cells Negative  
Dominant Lethal Assay *Drosophila* Negative  
Mammalian Cell Mutagenicity Mouse Lymphoma Positive

#### **Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))**

##### **Spironolactone**

104 Week(s) Rat Oral 10 mg/kg/day LOAEL Benign tumors  
52 Week(s) Non-human Primate Oral 20 mg/kg/day LOAEL Reproductive System

##### **Hydrochlorothiazide**

2 Year(s) Rat Oral 2000 ppm NOAEL Not carcinogenic  
2 Year(s) Female Mouse Oral 5000 ppm NOAEL Not carcinogenic  
2 Year(s) Male Mouse Oral 5000 ppm LOAEL Malignant tumors, Liver

**Carcinogen Status:** See below

##### **Povidone**

**IARC:** Group 3 (Not Classifiable)

##### **Iron oxide**

**IARC:** Group 3 (Not Classifiable)

##### **Titanium dioxide**

**IARC:** Group 2B (Possibly Carcinogenic to Humans)

##### **Spironolactone**

**IARC:** Group 3 (Not Classifiable)

##### **Hydrochlorothiazide**

**IARC:** Group 3 (Not Classifiable)

### 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

**Toxicity:** No data available

**Persistence and Degradability:** No data available

#### **Bio-accumulative Potential:**

**Partition Coefficient: (Method, pH, Endpoint, Value)**

##### **Spironolactone**

Predicted 7.4 Log D 3.12

**Mobility in Soil:** No data available

## SAFETY DATA SHEET

Material Name: Spironolactone and Hydrochlorothiazide  
Tablets (Greenstone LLC)  
Revision date: 11-May-2015

Page 10 of 13

Version: 2.0

### 13. DISPOSAL CONSIDERATIONS

**Waste Treatment Methods:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

### 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

### 15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

**Canada - WHMIS: Classifications**

**WHMIS hazard class:**

Class D, Division 2, Subdivision A



**Iron oxide**

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	215-168-2

**Flavor**

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

**Povidone**

CERCLA/SARA 313 Emission reporting	Not Listed
------------------------------------	------------

## SAFETY DATA SHEET

Material Name: Spironolactone and Hydrochlorothiazide  
 Tablets (Greenstone LLC)  
 Revision date: 11-May-2015

Page 11 of 13

Version: 2.0

### 15. REGULATORY INFORMATION

California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

#### Magnesium stearate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	209-150-3

#### Hydroxypropyl methylcellulose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	Not Listed

#### Hydrochlorothiazide

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	200-403-3

#### Hydroxypropyl cellulose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

#### Titanium dioxide

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	carcinogen initial date 9/2/11 airborne, unbound particles of respirable size
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	236-675-5

#### Calcium sulfate, dihydrate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

#### Spironolactone

## SAFETY DATA SHEET

Material Name: Spironolactone and Hydrochlorothiazide  
Tablets (Greenstone LLC)  
Revision date: 11-May-2015

Page 12 of 13

Version: 2.0

### 15. REGULATORY INFORMATION

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	carcinogen initial date 5/1/97
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	200-133-6

#### Polyethylene glycol

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 3
EU EINECS/ELINCS List	Not Listed

#### Corn Starch

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	232-679-6

### 16. OTHER INFORMATION

#### Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Reproductive toxicity-Cat.1B; H360D - May damage the unborn child  
Carcinogenicity-Cat.2; H351 - Suspected of causing cancer  
Specific target organ toxicity, repeated exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure

Carcinogenic: Category 3  
Toxic to Reproduction: Category 2  
Xn - Harmful

R40 - Limited evidence of a carcinogenic effect  
R61 - May cause harm to the unborn child.  
R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed.

**Data Sources:** The data contained in this SDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

**Reasons for Revision:** Updated Section 7 - Handling and Storage. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 12 - Ecological Information. Updated Section 11 - Toxicology Information. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 16 - Other Information.

**Revision date:** 11-May-2015

## SAFETY DATA SHEET

**Material Name: Spironolactone and Hydrochlorothiazide  
Tablets (Greenstone LLC)  
Revision date: 11-May-2015**

**Page 13 of 13**

**Version: 2.0**

---

**Prepared by:** Product Stewardship Hazard Communication  
Global Environment, Health, and Safety Operations

It is believed that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time

**End of Safety Data Sheet**